First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Intellia Therapeutics, Inc.

    NTLA · 5 developments mapped · last assessed 2026-09-12

    Market Ontology has mapped 5 macro, policy, and market developments to Intellia Therapeutics, Inc. since 2026-09-09. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for NTLA yet, so no modelled value is shown. The NTLA valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run NTLA on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for NTLA. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump

      Indirect positive sentiment for gene editing technology and platform validation. Potential for increased investor interest in the broader gene editing space.

      · Moves investor perception of gene editing platform risk, ability to raise capital

    • Open question

      Cellectis Schedules September 14 Business and CAR T Pipeline Update

      Second-order effect through sector sentiment. Cellectis's update on gene editing and CAR T development could influence investor perception of the broader gene editing and cell therapy space.

      · Moves sector wide investor sentiment for gene editing technologies, perceived regulatory environment for gene editing

    What changed, by assumption

    Investor perception of gene editing platform risk
    • 2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
    Probability of success for gene editing pipeline assets
    • 2026-09-09CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M
    Sector wide investor sentiment for gene editing technologies
    • 2026-09-12Cellectis Schedules September 14 Business and CAR T Pipeline Update
    Probability of success for pipeline assets
    • 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
    • 2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-06-15RevenueBullishPositive Phase 3 HAELO trial results for lonvo-z and initiated rolling BLA submission support potential U.S. launch in 1H 2027.0.90
    2026-06-15RevenueBullishPositive Phase 3 HAELO trial results for lonvo-z and initiated rolling BLA submission support future commercial launch in 2027.0.90

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-12Cellectis Schedules September 14 Business and CAR T Pipeline Updatewatch1-5d0.30
    2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales JumpBullish3-12m0.40
    2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MBullish3-12m0.30
    2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy CasgevyBullish1-3m0.30
    2026-09-09CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76MBullish3-12m0.40